IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants Serial No.

Simons et al. 09/145,916

Filed

September 2, 1998

For

September 2, 1998
'STIMULATION OF ANGIOGENESIS VAN

ENHANCED ENDOTHELIAL EXPRESSION

OF SYNDECAN-4 CORE PROTEINS"

Examiner

David Guzo

Group Art Unit

1636

Attorney's Docket No.

BIS-039

#16C

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on: <u>July 19,2001</u>.

Attorney for Applicants:

Signature:

Date:

THIRD AMENDMENT OF SPECIFICATION AND REQUEST FOR ENTRY OF A THIRD PAPER FORM COPY OF THE SEQUENCE LISTING CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In accompanyment with the enclosed Reply to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed April 2, 2001, as extended through August 2, 2001, applicants

respectfully amend the above-identified application by submission and entry of a third paper form copy of the sequence listing.

This third submission of the enclosed "Sequence Listing in paper form copy is made pursuant to and in compliance with the requirements set forth in 37 C.F.R. 1.821-1.825 respectively.

Applicants' undersigned attorney declares and verifies that this third amendment and requested formal entry of the third "Sequence Listing" in paper form copy is proper and correct in all respects; and that the enclosed third "Sequence Listing" in paper copy form is completely supported by the descriptive content and enabling disclosure of the Specification text originally filed September 2, 1998 as USSN 09/145,91

In addition, applicants' undersigned attorney further declares and verifies that the enclosed third "Sequence Listing" submitted in paper form copy does not contain or include any New Matter; and that a third submission of a computer readable form (CRF) copy of the third "Sequence Listing" is also provided, the third computer readable form (CRF) copy being identical in substantive content to the enclosed third paper form copy. Accordingly, this third paper form copy "Sequence Listing", after being formally entered into and made part of the Specification, is to be transferred to the custody of the Patent Examiner of record; and the formally entered third paper form copy

"Sequence Listings" shall now constitute part of the Specification text and may be employed by the Patent Examiner of record during the substantive prosecution of this application.

Respectfully submitted,

SIMONS et al.

Magnolia, Massachusetts 01930 Tel.: (978) 525-3794

Reg. No. 29,693 Attorney for applicants